KRAS and neoplasm: However, Cdkn2a inactivation increased tumor number in the KRAS G12D context more than in KRAS G12C, consistent with genomic analyses of human non-small cell lung cancers describing enrichment of CDKN2A mutations in tumor with KRAS G12D relative to KRAS G12C or other KRAS variants30,49,50.